Cost-effectiveness of psychological treatment and support interventions for people living with HIV/AIDS: state of the evidence and policy considerations Authors: Emmanuel Kumah, Dorothy Serwaa Boakye, Richard Boateng, Collins Kokuro, Samuel Egyakwa Ankomah, Adam Fusheini, Eunice Agyei Published: 2025 ABSTRACT AbstractBackgroundAntiretroviral therapy (ART) has significantly improved the survival and quality of life of people living with HIV (PLHIV). However, many still face persistent physical, emotional, and social challenges. Integrating psychological treatments into HIV care has demonstrated potential for enhancing mental health, improving treatment adherence, and achieving better clinical outcomes. While the effectiveness of these interventions is well-documented, evidence on their cost-effectiveness remains limited and lacks systematic synthesis. This study addresses this gap by evaluating the current evidence on the cost-effectiveness of psychological treatment and support interventions for PLHIV.MethodsA comprehensive search was conducted in PubMed, PsycINFO, Embase, and EconLit via EBSCO for English-language, peer-reviewed studies on the cost-effectiveness of psychological interventions for individuals living with HIV/AIDS. No restrictions were placed on the publication year. Searches were performed in January, June, August, and October 2024, supplemented by citation tracking. Three reviewers independently screened studies in two stages, resolving disagreements through discussion. Data were extracted using a standardized table aligned with Joanna Briggs Institute guidelines to capture study characteristics, interventions, outcomes, and methodologies. Study quality was assessed using the Quality of Health Economic Studies (QHES) instrument.ResultsOut of 3,410 records identified, 2,852 remained after duplicate removal, and eight studies met the inclusion criteria. Studies were conducted in the USA (n = 3), Uganda (n = 3), the Netherlands (n = 1), and Tanzania (n = 1), using randomized controlled trials, observational designs, and modeling approaches. Seven of the eight interventions demonstrated cost-effectiveness when evaluated against country-specific willingness-to-pay thresholds. Reported incremental cost-effectiveness ratios ranged from $13–$397 per DALY averted in low-income settings and $13,316–$36,166 per QALY gained in high-income settings, consistently falling below accepted thresholds. Several interventions showed high probabilities of cost-effectiveness (≥ 94%) and, in some cases, cost savings. One psychosocial group intervention in Tanzania exceeded GDP-based thresholds but was still considered a potentially affordable alternative given limited access to mental health services.ConclusionThe findings indicate that psychological treatment and support interventions for PLHIV are generally cost-effective across both developed and developing settings, enhancing mental health outcomes while optimizing healthcare resource use. However, the evidence base remains limited to eight studies from four countries, underscoring the need for further research across diverse contexts to reinforce the economic case for integrating psychological services into HIV care frameworks.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12962-025-00707-8.Keywords: Cost-effectiveness, Psychological treatment, People living with HIV, Systematic review Introduction The HIV/AIDS epidemic continues to be a major global health challenge [1–3], with an estimated 39.9 million people living with HIV worldwide as of 2023 [4]. While the introduction of antiretroviral therapy (ART) has significantly improved survival rates and quality of life for people living with HIV (PLHIV) [4, 5], many still face significant physical, emotional, and social challenges [6, 7]. Mental health disorders, particularly depression and anxiety, are highly prevalent among PLHIV, with estimates ranging from 20 to 50% in various settings [8]. A review of the literature estimates that 24% of PLHIV in sub-Saharan Africa experience depression, compared to less than 3% of the general population [9]. In the United States, a study of 10,652 PLHIV across seven urban HIV care sites found that 48% had a substance use disorder, including marijuana (31%), alcohol (19%), methamphetamine (13%), cocaine (11%), and opioids (4%), with 20% exhibiting polysubstance use [10]. Adolescents with HIV generally show higher rates of mental health issues, such as depression and anxiety, than their HIV-negative peers [11]. Additionally, PLHIV are much more likely to have suicidal thoughts and die by suicide than the general population, with a systematic review and meta-analysis indicating a 100-fold higher suicide death rate in this group [12]. Key populations (sex workers, men who have sex with men, transgender people, people who inject drugs, and individuals in prisons or other closed settings) frequently face stigma, discrimination, and social marginalization, which, along with vulnerability to HIV and rights violations, lead to increased emotional distress and mental health problems [13]. These mental health issues can negatively affect treatment adherence, disease progression, and overall quality of life. Integrating psychological treatment and support interventions into HIV care has the potential to improve mental health outcomes, treatment adherence, and ultimately, clinical outcomes for PLHIV. A growing body of evidence suggests that interventions such as cognitive-behavioral therapy (CBT), group support psychotherapy, and adherence support programs can be effective in reducing depression and anxiety symptoms and improving quality of life among PLHIV [14–16]. Many key policies and international bodies support integrating mental health care into HIV treatment programs. The World Health Organization (WHO) recommends integrating mental health services into routine HIV care to address untreated mental health problems that undermine engagement and adherence [17]. UNAIDS similarly emphasizes mental health as integral to ending the AIDS epidemic, highlighting the cost-effectiveness of integrated care models [4]. South Africa’s new National Strategic Plan for HIV, TB, and STIs (2023–2028) also prioritizes this approach, aligning with WHO guidance [8]. Likewise, the Global AIDS Strategy 2021–2026 and the United Nations Political Declaration on HIV and AIDS stress the importance of integrated services and community-led interventions to strengthen outcomes for people living with HIV [18, 19]. Numerous studies have examined the effectiveness of integrating mental health services into HIV care [20–25]. A scoping review of 29 studies from developed and developing countries revealed that integrating mental health services into HIV care resulted in reductions in depression, alcohol use, and psychiatric symptoms among people living with HIV, as well as improvements in social functioning and decreased self-reported stigma. Furthermore, healthcare workers reported feeling more comfortable discussing mental illness with their patients, while mental health professionals noted reduced stigma and increased referrals of PL HIV to mental health services [26]. However, evidence on the cost-effectiveness of these interventions remains limited, and to the best of our knowledge, no study has systematically reviewed the existing evidence to draw robust conclusions about their economic viability. Cost-effectiveness analysis (CEA) is a useful tool for evaluating the value of healthcare interventions by comparing their costs and health outcomes. CEA can help inform resource allocation decisions and ensure that limited healthcare resources are directed towards interventions that provide the greatest health benefit per dollar spent [27]. In the context of HIV and mental health, CEA can help determine whether the added costs of integrating psychological treatment and support interventions into HIV care are justified by the resulting improvements in health outcomes and quality of life. By calculating the incremental cost-effectiveness ratio (e.g., cost per quality-adjusted life year gained), CEA provides a comparative metric to assess the value for money of different intervention options [28, 29]. The purpose of this study, therefore, is to systematically review and synthesize the current evidence on the cost-effectiveness of psychological treatment and support interventions for PLHIV, with a focus on identifying key knowledge gaps and policy considerations. By doing so, we aim to inform decision-makers and stakeholders in the HIV and mental health sectors about the potential value of integrating these interventions into HIV care. Investing in cost-effective interventions to address the mental health needs of PLHIV not only supports mental well-being [30, 31] but also contributes to achieving the UNAIDS 95-95-95 targets for HIV diagnosis, treatment, and viral suppression, ultimately advancing efforts to end the HIV/AIDS epidemic as a public health threat by 2030 [32]. Methods This systematic review was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [33] and reported using the Preferred Reporting items for Systematic Reviews and Meta-Analysis (PRISMA) statement [34]. Eligibility criteria Using an adapted version of the population, intervention, comparison and outcome (PICO) framework to include “S” for study design (PICOS), the inclusion criteria for this review are detailed in Table 1. Table 1Inclusion criteria based on the adapted PICOS frameworkComponentInclusion criteriaPopulationStudies involving people living with HIV (PLHIV) of any age, gender, or geographical locationInterventionStudies evaluating the cost-effectiveness of psychological treatment and support interventions for PLHIV, including but not limited to cognitive behavioral therapy (CBT), group support psychotherapy, adherence support programs, and integrated mental health and HIV care modelsComparatorStudies comparing psychological interventions to standard of care, usual care, or alternative interventionsOutcomesStudies reporting cost-effectiveness outcomes, such as incremental cost-effectiveness ratio (ICER), cost per quality-adjusted life years (QALY) gained, cost per disability-adjusted life years (DALY) averted, cost per reduction in depression or anxiety symptoms, or cost per improvement in quality of lifeStudy DesignRandomized controlled trials (RCTs), observational studies (including cohort studies, case-control studies, and cross-sectional studies), modeling studies, and economic evaluations Inclusion criteria based on the adapted PICOS framework Studies that were not published in English were excluded. Additionally, case reports, case series, qualitative studies, editorials, commentaries, letters to the editor, and non-peer-reviewed publications were excluded. Information sources and search strategy A comprehensive literature search was conducted across PubMed, PsycINFO, Embase, and EconLit via EBSCO, focusing on English-language, peer-reviewed publications. The search had no restrictions on publication year. The strategy was designed using terms related to three key elements: cost-effectiveness, psychological treatment or support interventions, and people living with HIV/AIDS (Table 2). As an example, the full search strategy for PubMed is provided as a supplementary file (see Supplementary File 1). The initial search was conducted in January 2024, followed by additional searches in June, August, and October 2024. To ensure thoroughness, we also performed backward and forward citation tracking by reviewing reference lists and citations from the included studies to identify any relevant studies that might have been missed during the database search. Table 2Search strategy for the systematic reviewNo.KeywordsSearch Terms1Cost-effectivenesscost-effectiveness OR cost utility OR cost efficiency OR cost outcome OR cost minimization OR economic evaluation OR economic impact OR economic burden OR “value for money” OR financial feasibility2Psychological treatment or support interventionpsychotherapy OR pharmacotherapy OR psychological therapy OR psychosocial intervention OR psychosocial treatment OR cognitive therapy OR “mental health treatment” OR “mental health therapy” OR psychiatric care OR “emotional support therapy” OR psychosocial support OR psychological counseling OR “social support intervention”3People living with HIV/AIDS“people living with HIV” OR “people living with AIDS” OR “individuals affected by HIV” OR “people diagnosed with HIV” OR “persons living with HIV” OR “HIV-positive individuals” OR “HIV-affected persons”41–3 combined with “AND” Search strategy for the systematic review Study selection and data extraction The selection and inclusion of papers for this review involved a two-stage process. First, all publications retrieved through the search were imported into a shared bibliography, and duplicate records were removed. Three independent reviewers (EK, DSB and RB) then applied the eligibility criteria to screen the titles and abstracts for potential eligibility. Articles meeting the criteria were selected for full-text review, where the reviewers again independently assessed each article for final inclusion based on the same criteria. At each stage, the reviewers compared their results and resolved disagreements through discussion, with a third reviewer (CK) serving as a tiebreaker when consensus could not be reached. Characteristics of the selected studies were extracted using a standardized table adapted from the Joanna Briggs Institute’s economic evaluation guidelines and prior economic evaluation reviews [35–40]. Information extracted included author names, publication year, country, study sample characteristics, intervention details, usual care (UC) or control/comparator group, perspective, time horizon, evaluation type (e.g., CEA or cost-utility analysis), outcomes (e.g., ICER, QALY, DALY), study design, cost categories, cost-effectiveness threshold, and cost-effectiveness results. Data extraction was conducted by EK and DSB, with AF and SEA performing a double-check. Any disagreements were resolved through discussions among the authors. Quality assessment The methodological quality of the included studies was assessed using the Quality of Health Economic Studies (QHES) instrument [41], which evaluates the quality of cost-effectiveness analyses (CEAs) through a checklist of 16 criteria. These criteria, assessed with dichotomous “yes” or “no” responses, cover aspects such as the clarity of the study objective, the stated perspective of the analysis, the handling of uncertainty, the performance of incremental analysis, and the appropriateness of methods for data abstraction and cost measurement (see Supplementary File 2). Each criterion is assigned a weighted point value, ranging from 3 to 9, and the methodological quality score is calculated by summing the points for all criteria marked “yes.” The maximum possible quality score is 100 points [41]. Two reviewers (EK and DSB) independently conducted the quality assessment, with any discrepancies resolved through discussion. Studies were classified into quality categories based on the following cut-off points: extremely poor quality (0–24), poor quality (25–49), fair quality (50–74), and excellent quality (75–100). Results Our initial search identified 3410 records, which were reduced to 2852 after duplicate removal. Following title and abstract screening, 70 records were selected for full-text assessment. Ultimately, 8 studies met the inclusion criteria and were included in the review. The literature search process is detailed in the PRISMA flowchart (Fig. 1). Literature search flow diagram Characteristics of the included studies A detailed description of the included studies is presented in Table 3. The studies were conducted in both developed and developing countries. Three studies were conducted in the USA [42–44] and one in the Netherlands [47], representing developed contexts, while three studies were conducted in Uganda [45, 46, 48] and one in Tanzania [49], representing developing contexts. Study designs varied, including randomized controlled trials [42,45–47, observational or cross-sectional studies [43, 44], and microsimulation modeling [48]. Sample sizes ranged from 139 [43, 44] to 1,473 [46] individuals living with HIV, focusing on subgroups such as older adults [43, 44], perinatal women [45], and individuals with depressive symptoms [47, 49]. Table 3Characteristics of the included studiesStudy, CountryStudy design and sampleEvaluation type and outcomesInterventionControl orComparatorDelaCruz et al. [43, USAA non-RCT of 139 HIV-infected adults (50 years or older)CEA and outcomes are measured in QALYsAn integrated medical and behavioral care system that provides older adults living with HIV with both ART and mental health treatment to address depression and substance use disordersMedical care onlyDelaCruz et al. [44], USAA non-RCT of 139 HIV-infected adults (50 years or older)CEA that compared the cost per quality-adjusted life-year QALY gainedA combined strategy that includes both HIV medical and behavioral care (ART + Behavioral)HIV medical care only (ART only)McBain et al. [45], UgandaA cluster RCT of 391 perinatal women living with HIV (Intervention = 191, Control = 200)CEA and outcome measured in DALYsMaternal Depression Treatment in HIV (M-DEPTH), a task shifted, evidence-based collaborative care model for perinatal depression among women living with HIVUsual careNakimuli-Mpungu et al. [46], UgandaA pragmatic two-arm cluster-RCT of 1473 individuals, aged 19 and above, living with HIV (intervention = 578, control = 562)CEA, with the outcomes being DALYsGroup support psychotherapy (GSP) delivered by trained lay health workers once a week for 8 weeks 2Group HIV education (GHE) delivered by similar lay health workers in a similar format to GSPPainter et al. [42], USARCT of 249 HIV-infected patients (intervention = 123, control = 126)CEA and outcome measured in QALYsAn off-site depression care team (nurse, pharmacist, psychiatrist) that collaborated with on-site HIV providers. The nurse depression care manager provided patients with education, monitoring, and self-management support via telephone, using a stepped-care model for depression treatment based on established guidelinesUsual carevan Luenen et al. [47], the NetherlandsRCT of 188 PLHIV > 17 years old (Intervention = 97, control = 91)CUA with the outcomes being QALYsA guided 8-week Internet-based cognitive behavioral therapy (CBT) program for people living with HIV and depressive symptoms. The program consisted of 1–2 h per week of online CBT-based content, along with 15 min per week of telephone coaching support from trained graduate-level psychology students.Participants received attention only from a coachZhong et al. [48], UgandaA microsimulation modeling studyCEA, with the outcomes being QALYsA pharmacological intervention of using fluoxetine to treat depression among PLHIV.Care as usualSaronga et al. [49], TanzaniaRCT of 742 perinatal women, 18 years and above, living with HIV and depression (intervention = 395, control = 347)CEA and outcome measured in DALYsProblem-solving therapy group sessions before delivery, with 1 orientation and 6 sessions for 15–20 women per group, and cognitive behavioral therapy group sessions for women with continued depressive symptoms at 6 weeks postpartum, with 8 sessions for 8–10 women per groupUsual careART = antiretroviral therapy, CEA = cost-effectiveness analysis, DALY = disability adjusted life year, QALY = quality adjusted life year, RCT = randomized controlled trialCUA = cost utility analysis, RCT = randomized controlled trial, PLHIV = people living with HIV, Microsimulation modeling study – a computer-based method that simulates individual-level outcomes over time to predict the impact of interventions Characteristics of the included studies ART = antiretroviral therapy, CEA = cost-effectiveness analysis, DALY = disability adjusted life year, QALY = quality adjusted life year, RCT = randomized controlled trial CUA = cost utility analysis, RCT = randomized controlled trial, PLHIV = people living with HIV, Microsimulation modeling study – a computer-based method that simulates individual-level outcomes over time to predict the impact of interventions Most studies (7 out of 8) employed cost-effectiveness analyses (CEA) [42–46, 48, 49], while only one study used cost-utility analysis (CUA) [47]. Outcomes were measured using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). QALYs were predominantly used in five studies evaluating integrated medical and behavioral care or pharmacological interventions [42–44, 47, 48]. In contrast, DALYs were used in four studies: two conducted in Uganda [44, 46] and one in Tanzania [49], all addressing the burden of maternal depression and group psychotherapy interventions. The interventions varied in their approach and focus. Behavioral and psychological interventions were a key component in many studies, including group support psychotherapy [46], internet-based cognitive behavioral therapy [47], and collaborative care models for depression treatment [42, 45]. Pharmacological interventions, such as fluoxetine for depression, were explored in Zhong et al. [48]. Integrated medical and behavioral care systems, combining antiretroviral therapy (ART) with mental health services, were examined in DelaCruz et al. [43, 44]. Comparators across studies included standard HIV care [41, 42], group education [44], or care as usual [42, 45, 48, 49]. Cost and cost-effectiveness of the interventions The key elements in estimating the cost in each study are summarized in Table 4. The perspective taken for the costing significantly influences the inclusion of cost items. The healthcare perspective was the most common, as seen in studies by DelaCruz et al. [43, 44], Nakimuli-Mpungu et al. [46], Zhong et al. [48], and Saronga et al. [49]. These studies generally included direct costs such as intervention setup and operation expenses, training, and medical care. In particular, DelaCruz et al. [43] and Zhong et al. [48] provided detailed breakdowns, covering both treatment and associated healthcare costs, such as ART and diagnostic tests. The remaining three studies adopted a societal perspective, which broadened the scope of costs to include indirect expenses, such as patient opportunity costs, travel, and productivity losses. McBain et al. [45] and Painter et al. [42] offered comprehensive societal cost analyses, with McBain et al. accounting for opportunity costs to patients alongside programmatic expenses. Similarly, van Luenen et al. [47] included healthcare and non-healthcare costs, such as productivity losses, providing a broader view of economic implications. Table 4Summary of cost and cost-effectiveness of the reviewed interventionsStudyPerspectiveCost categoriesTime horizon, discount rateThresholdCost-effectiveness resultsDelaCruz et al. [43]HealthcareAnnual cost of integrated HIV and mental health/substance abuse treatmentTime horizon of 50 years, discount rate of 3%$50,000 per QALY gainedThe incremental cost was $516,452 and the incremental effectiveness was 38.8 QALY, with an ICER of $13,316 per QALYDelaCruz et al. [44]HealthcareIntegrated medical, mental health, and substance abuse care costsA 3% discount rate applied to costs and effectiveness occurring at a future timeA WTP of $75,000 per QALYThe ICER for the intervention compared to ART alone was $36,166 per QALY gained.The probabilistic sensitivity analysis showed the intervention was cost-effective 94.2% of the timeMcBain et al. [45]SocietalStaff time and salaries, clinical space and infrastructure, consumables (medications, materials, refreshments), training, supervision, opportunity costs to patientsThe analysis used a 0% discount rate, with sensitivity tests for 3- and 5-year horizons at 3% and 5%. A 5-year horizon at 3% was applied to each age groupA WTP of $964 per DALY averted, Based on WHO-CHOICE cost-effectiveness thresholdsThe intervention was highly cost-effective, producing an average ICR of US$397 DALY avertedScale-up would represent less than 0.5% of the Ugandan health budget, and this investment could pay for itself by reducing the economic burden associated with perinatal depressionNakimuli-Mpungu et al. [46]Health-care sectorTraining, facilitation, supervision costs development of learning materials and training manuals, value of voluntary timeTime horizon of 5 years for each age group, and a discount rate of 3%.$606 per DALY averted, which was the Uganda GDP per capita in 2017The intervention was found to be very cost-effective, with an ICER of $13 per DALY averted, which is lower than the GDP per capita in Uganda.Painter et al. [42]SocietalIntervention costs, healthcare expenditures. patient costsThe time horizon of the study was 12 months, no discounting applied$50,000 per QALY gainedThe intervention was highly cost-effective, with a 96.4% probability of costing less than $20,000 per QALY and a 77.8% probability of being cost-savingvan Luenen et al. [47]SocietalIntervention costs (website and coaching), healthcare costs, and non-healthcare costs (productivity losses).The time horizon for the analysis was 6 months, and no discount rate was appliedEvaluated the cost-effectiveness of the intervention across a range of potential WTP thresholds up to €100,000 per QALYThe cost-utility acceptability curve of the sensitivity analysis with only healthcare costs included shows that for all values of WTP > €5000, the intervention demonstrates a higher probability to be cost-effective, compared to attention only. Including ART costs in the medication costs, lead to mean additional costs of €2802 in the intervention group and €3657 in the control group, with no significant differences between groups (difference: -856; 95% CI: -2005, 294)Results of the sensitivity analysis including ART costs indicate that the intervention has a higher probability of being cost-effective for all values of WTP, compared to attention onlyZhong et al. [48]Healthcare systemFluoxetine, CD4 tests, viral load tests, first-line and second-line ART, HIV tests, HIV-related inpatient and outpatient care, and non-HIV healthcareTime horizon of 10 years and a discount rate of 3%A WTP of $631 per QALYThe intervention cost $15/QALY gained compared to the status Extrapolation to the population level revealed that the intervention would cost $12.13 million and gain 790,000 QALYs over the analytic time horizon.Saronga et al. [49]Health care providerOffice supplies and equipment, communication, personnel (psychiatrist, facilitators, supervisors, coordinator), training materials, transport, training refreshments, participant travel and stipends, and annuitized building and furniture costsTime horizon of 3 years2017 GDP per capita for Tanzania of $975.9Total cost of the intervention over 3 years was $319,729. The incremental cost-effectiveness ratio (ICER) was $89,699 per mean decrease in depression score at 6 weeks and $310,030 per mean decrease at 9 months. The ICER per DALY averted was $24,754 at 6 months and $4,169 at 9 months. Sensitivity analysis showed the ICER per DALY averted ranged from $17,906 to $54,354 at 6 weeks and $3,353 to $4,977 at 9 months. However, the ICER per DALY averted was still above the cost-effectiveness threshold of the 2017 GDP per capita for Tanzania, so the Healthy Options intervention was not considered cost effective.DALY = disability adjusted life year, QALY = quality adjusted life year, GDP = Gross Domestic Product, WTP = Willingness to payART = antiretroviral therapy Summary of cost and cost-effectiveness of the reviewed interventions The ICER for the intervention compared to ART alone was $36,166 per QALY gained. The probabilistic sensitivity analysis showed the intervention was cost-effective 94.2% of the time The intervention was highly cost-effective, producing an average ICR of US$397 DALY averted Scale-up would represent less than 0.5% of the Ugandan health budget, and this investment could pay for itself by reducing the economic burden associated with perinatal depression The cost-utility acceptability curve of the sensitivity analysis with only healthcare costs included shows that for all values of WTP > €5000, the intervention demonstrates a higher probability to be cost-effective, compared to attention only. Including ART costs in the medication costs, lead to mean additional costs of €2802 in the intervention group and €3657 in the control group, with no significant differences between groups (difference: -856; 95% CI: -2005, 294) Results of the sensitivity analysis including ART costs indicate that the intervention has a higher probability of being cost-effective for all values of WTP, compared to attention only DALY = disability adjusted life year, QALY = quality adjusted life year, GDP = Gross Domestic Product, WTP = Willingness to pay ART = antiretroviral therapy The cost-effectiveness of the majority of the interventions (7 out of 8), evaluated against their respective willingness-to-pay (WTP) thresholds, demonstrated economic viability across various settings and contexts (Table 4). DelaCruz et al. [43] found that an integrated medical and behavioral health intervention had an incremental cost-effectiveness ratio (ICER) of $13,316 per QALY, well below their WTP threshold of $50,000 per QALY gained [43], indicating cost-effectiveness. Similarly, DelaCruz et al. [44] found that adding behavioral interventions to ART yielded an ICER of $36,166 per QALY, below a $75,000 per QALY threshold [44], and was cost-effective 94.2% of the time according to probabilistic sensitivity analysis. McBain et al. [45] evaluated the Mental Health and Depression Treatment for people with HIV (M-DEPTH) intervention, which achieved an ICER of $397 per DALY averted, well under the WHO-CHOICE guideline threshold of $964 per DALY averted [50], confirming its high cost-effectiveness. Nakimuli-Mpungu et al. [46] assessed group support psychotherapy (GSP) in Uganda, where the intervention’s ICER of $13 per DALY averted was significantly below the 2017 GDP per capita threshold of $606 for Uganda [51], indicating exceptional cost-effectiveness. Painter et al. [42] found that the HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) collaborative care intervention for depression among people living with HIV had a 96.4% probability of costing less than US$20,000 per QALY and a 77.8% probability of being cost-saving, underscoring its economic attractiveness at a WTP threshold of US$50,000 per QALY [42]. van Luenen et al. [47] did not specify a single WTP threshold but demonstrated that their intervention remained cost-effective at all values exceeding €5,000 per QALY [47], reinforcing its economic viability. Finally, Zhong et al. [48] evaluated an intervention with an ICER of $15 per QALY gained, far below the $631 per QALY threshold [48], and projected it could generate 790,000 QALYs over 10 years at a cost of $12.13 million, highlighting its potential for large-scale implementation. Only one intervention, Healthy Options — a psychosocial support group intervention assessed by Saronga et al. [49] in Tanzania — was not found to be cost-effective. The authors reported ICERs per DALY averted of $24,754 at 6 months and $4,169 at 9 months, both exceeding the 2017 GDP per capita for Tanzania ($975.9) [51], which served as the cost-effectiveness threshold. Nevertheless, they concluded that, given the scarcity of mental health care services in Tanzania, the psychosocial support group could still offer a less costly alternative to care provided by formal mental health professionals. Methodological quality of the included studies The quality scores of the included studies ranged from 71 to 88. Among them, two studies [42, 49] were classified as fair quality, while the remaining studies [43–48] achieved excellent quality. This reflects robust methodological rigor, particularly in outcome measurement, cost analysis, and transparency. The overall average quality score across all studies was 80.9, indicating strong adherence to quality criteria. However, some quality gaps were identified. In the data collection and reporting domain, the most commonly unmet criterion was insufficient disclosure of the methodology for data abstraction, observed in several studies [42–44, 46–49]. Additionally, in the bias and uncertainty domain, explicit discussions of the direction and magnitude of potential biases were notably absent in most studies [42–45, 47, 49]. Total quality score for each study is presented in Fig. 2, with details provided in Supplementary File 3. Methodological quality scores of the reviewed studies Discussion This review demonstrates that psychological treatment and support interventions for people living with HIV/AIDS (PLHIV) are economically viable, with most interventions falling below their respective willingness-to-pay thresholds. These findings highlight the dual benefit of psychological interventions: they not only improve individual health outcomes but also promote the efficient allocation of limited healthcare resources. This dual impact reinforces the importance of considering mental health services as a core component of comprehensive HIV care strategies, rather than as ancillary or supplementary services. The observed economic viability aligns with a growing body of evidence supporting the value for money offered by mental health interventions. Studies such as Mutyambizi-Mafun et al. [50], Nicklas et al. [52], and Le et al. [40] have consistently shown that mental health programs significantly enhance well-being while remaining cost-effective, even in resource-constrained settings. Moreover, the present findings are congruent with broader cost-effectiveness analyses of HIV-related interventions. For example, Creese et al. [53] demonstrated the economic value of interventions aimed at HIV prevention, while Iacob et al. [37] highlighted the cost-effectiveness of strategies to improve adherence to antiretroviral therapy (ART). Similarly, Dalal et al. [54] confirmed the economic viability of interventions promoting the uptake of HIV testing services. By positioning psychological treatment and support interventions within this established evidence base, the argument for their formal integration into HIV care becomes even stronger. A major strength of this review is the high methodological quality of the included studies. Quality appraisal showed a strong average score (mean 80.9/100), reflecting consistent adherence to established best practices for conducting and reporting economic evaluations. Additionally, the review adopted a broad and inclusive search strategy that captured diverse populations, healthcare settings, and psychological interventions, including cognitive-behavioral therapy, adherence support programs, and group psychotherapy. This diversity enhances the comprehensiveness and applicability of the findings across both low- and high-income contexts. However, a critical limitation of the evidence base emerges: the findings rest on a relatively narrow data pool. Specifically, the studies included in this review were conducted in three out of the six WHO regional classifications—namely, the Region of the Americas, the African Region, and the European Region. The absence of studies from the Asia Region, Eastern Mediterranean Region, and Western Pacific Region limits the global generalizability of the findings. Context-specific factors, including cultural attitudes toward mental health, health system capacity, and socio-economic disparities, may influence both the effectiveness and cost-effectiveness of interventions and must be considered when interpreting the results [54]. Another limitation relates to the reporting of participant demographics. Most included studies provided only broad demographic information, typically reporting participants as “adult individuals living with HIV aged 18 years and above,” [43, 44] without further details on education, marital status, or religious affiliation. Consequently, our review could only report data that were explicitly available, which constrains the depth of analysis and limits the ability to explore potential demographic influences on intervention outcomes. Methodological challenges identified within the included studies also impact the robustness of the evidence. DelaCruz et al. [43], for example, highlighted issues such as the use of non-probability samples, restrictive assumptions within Markov models, and insufficient attention to fairness and equity concerns. McBain et al. [45] noted the exclusion of societal costs, such as informal caregiving and absenteeism, and a lack of long-term follow-up data to capture sustained intervention effects. Similarly, van Luenen et al. [47] and Nakimuli-Mpungu et al. [46] reported concerns related to recall bias, detection bias, and reliance on simplifying assumptions in modeling. These methodological issues could affect the reliability and validity of cost-effectiveness findings. The review itself is not without limitations. The exclusion of non-English language studies raises the possibility of language bias, potentially omitting significant evidence from non-English-speaking regions. Furthermore, reliance on published studies introduces the risk of publication bias, as studies reporting negative or non-significant findings may be underrepresented in the literature. Although a comprehensive search strategy was employed, these limitations suggest that the results should be interpreted with some caution. Despite these constraints, this review offers valuable insights into the economic viability of psychological interventions for PLHIV. Conclusion and implications for policy, practice, and research This review synthesized evidence on the cost-effectiveness of psychological treatment and support interventions for PLHIV. Interventions such as group psychotherapy, cognitive-behavioral therapy, and integrated medical-behavioral care were found to be economically viable, falling within established willingness-to-pay thresholds while improving mental health outcomes. These findings reinforce the importance of embedding psychological support as a core component of comprehensive HIV care, rather than viewing it as ancillary or secondary. Given the limited number of studies—only eight from four countries—caution is warranted in generalizing the results. Nonetheless, the evidence suggests that policymakers should prioritize integrating psychological interventions into national HIV treatment guidelines. International bodies such as WHO and UNAIDS can play a vital role by endorsing and supporting the widespread adoption of such interventions, particularly in low- and middle-income countries where mental health services remain underdeveloped [46]. To support effective implementation, healthcare systems should develop standardized methods for evaluating the cost-effectiveness of psychological interventions and invest in training healthcare workers to deliver these services within HIV care models. Strengthening health systems to integrate mental health services would further reduce stigma and enhance the holistic care of PLHIV [13]. Future research should extend economic evaluations to a broader range of socio-economic, cultural, and geographical contexts. Studies capturing societal costs—such as productivity losses and informal caregiving—combined with longer follow-up periods, sensitivity analyses, and transparent reporting practices will be essential to strengthen the evidence base [45]. Robust and context-specific data will be critical for making a stronger economic case for prioritizing psychological treatment and support interventions within global HIV care strategies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Acknowledgements Not applicable. Abbreviations Antiretroviral Therapy Cost-Effectiveness Analysis Human Immunodeficiency Virus Disability Adjusted Life Year Incremental Cost-Effectiveness Ratio Quality Adjusted Life Year World Health Organization Author contributions EK conceived and designed the paper. EK and DSB conducted the literature search. EK DSB, RB, CK, SEA, AF and EA screened the titles, abstracts and full-texts of the retrieved publications. EK drafted the manuscript and revised it for intellectual content. DSB, RB, SEA, AF and EA provided critical review of the paper. All authors read and approved the final version to be published. Funding No funding was obtained for this study. Data availability The data used in this analysis are available from the corresponding author on request. Declarations Ethics approval and consent to participate As the study is a review of existing literature and does not involve human participants or animal subjects, it did not require the approval of an ethics committee. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Data Availability Statement The data used in this analysis are available from the corresponding author on request.